Haemophilus Influenzae Bronchitis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for haemophilus influenzae bronchitis. 1 active patents protecting 1 drugs from 0+ originators. First major cliff: 2028. Daily refresh.

1
Approved drugs
1
Active US patents
75/100
Avg vulnerability
—
Annual revenue covered

Originators in Haemophilus Influenzae Bronchitis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating haemophilus influenzae bronchitis. Each bar = one year. Y-axis scaled to peak year (1 patents).

1
28

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Suprax
CEFIXIME
 — 1 75 — 2028-12-14

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9233112 Suprax method of use 75 2028-12-14

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9233112 Suprax method of use 75 2028-12-14

Related